Please tell us what you thought about today’s presentation by taking the survey below:
There is a significant unmet need for patients with Major Depressive Disorder (MDD) who fail to achieve an adequate response to current treatments. As our understanding of the biology of depression evolves, novel treatment targets are emerging. Neurobehavioral therapies (NBTs) that affect changes in potential mechanisms underlying depression are being explored. In this webinar, Dr. Robin Nelson, MD and Dr. Sandeep Vaishnavi, MD, PhD, will review the potential importance of neurocircuitry and neuroplasticity in MDD. They will also discuss the potential utility of using digital mental health treatments (DMHTs) to target neurobiological emotional control systems.
Psychiatrist, DGR Behavioral Health LLC & Caron Treatment Centers
Faculty, Duke Institute for Brain Sciences (DIBS), Duke University
Senior Medical Science Liaison
Speakers Robin Nelson, MD and Sandeep Vaishnavi, MD, PhD are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Speaker Mark Tacelosky, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Notifications
